



**New York State Medicaid Drug Utilization Review (DUR) Board Meeting
Room 3, Concourse Level, Empire State Plaza, Albany NY
February 26, 2026
10:00am to 3:00pm**

The meeting will be available for public viewing as a live and archived webcast
[Department of Health Events and Webcasts](#)

10:00 – 10:15 Welcome and Introductions

10:15 – 11:15 Public Comment Period

11:15 – 12:00 Drug Utilization Review

The DUR Board will review the following topic(s) and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Treatment guidelines for Atopic Dermatitis inclusive of the following drugs and drug classes:

- Doxepin Cream*
- Immunomodulators – Systemic
- Immunomodulators & Related Agents – Topical
- Steroids – Topical*

* The review of the drug or drug class will include indications other than Atopic Dermatitis.

The drugs within the classes listed above can be found on [NYRx Preferred Drug List \(PDL\)](#).

12:00 – 12:30 High-Cost Drug Review / Drug Utilization Review

The DUR Board will review the following drug(s), which has been identified as a high cost drug per [New York State Social Services Law 367-A](#) and if applicable, recommend a supplemental rebate target amount, clinical criteria, or interventions to ensure appropriate utilization:

- Daybue (trofinetide)

12:30 – 1:15 Lunch / Executive Session

High-Cost Drug Financial Review

1:15 – 1:30 High-Cost Drug / Drug Utilization Review Recommendations



1:30 – 2:30 Drug Utilization Review (continued)

The DUR Board will review the following topic(s) and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

2. Treatment of Headaches with the following drug classes:
 - Butalbital-Containing Agents
 - Ergotamine Derivatives
3. Treatment of Menopausal Vasomotor Symptoms with the following drug class:
 - Neurokinin Receptor Antagonists

2:30 – 2:45 Pharmacy Program Updates

1. Treatment of Ulcerative Colitis and Crohn’s Disease inclusive of the following drug classes:
 - Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
 - Non-Specific Anti-Inflammatory Drugs
2. [Cost Optimization Program](#)

2:45 – 3:00 Final Comments and Adjournment

The agenda timeline is subject to change based on meeting proceedings.

Additional Information

Parties interested in providing public comments during the DUR Board meeting, must complete the registration process by February 18, 2026. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment to meet agenda timelines and accomplish meeting objectives.

Written statements and clinical information can be sent to dur@health.ny.gov. Any studies cited should be referenced, with the primary source of funding included.

Written statements should summarize key points and may not exceed two (2) pages in length. Written statements must be received by February 18, 2026.



Any significantly detailed clinical information must be received by February 11, 2026.

All information must be sent to the Department of Health. Interested parties should not contact or send any information directly to DUR Board members.

DUR Board Members may participate by [videoconferencing from a non-public location under extraordinary circumstances](#) if unexpected factor or event precludes physical attendance.

Other Meeting Locations

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Abbott Hall Room 130
Buffalo, NY 14214

SUNY Global Center
Boardroom
116 East 55th Street, New York, NY 10022
